0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Pamidronate for Cancer-Associated Hypercalcemia-Reply

Rasim Gucalp, MD; Robert Knight, MD
Arch Intern Med. 1995;155(6):642-645. doi:10.1001/archinte.1995.00430060105016.
Text Size: A A A
Published online

In reply  Anand and Anand raised some interesting questions about the treatment of cancer-associated hypercalcemia. The role of parathyroid hormone—related protein (PTHrP) in cancer-associated hypercalcemia is the focus of intense research. Many studies1-4 suggest that increased PTHrP levels negatively influence the response of hypercalcemia to bisphosphonates. Walls et al4 reported that circulating PTHrP significantly reduced the effectiveness of pamidronate in patients with no bone metastases. However, in two randomized, prospective, double-blind studies5,6 of cancer-associated hypercalcemia, we demonstrated that the efficacy of pamidronate therapy was similar in patients with and without bone metastases. Some studies3 have shown a positive correlation between increased PTHrP concentrations and corrected serum calcium levels, but others1,2 have not confirmed this. Many different PTHrP detection methods are currently in use.7,8 This makes it difficult to compare the relative role of PTHrP in published studies. Additionally, the prediction of a poor response

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();